retatrutide clinical trial results obesity Another Promising Medication (Retatrutide) for Eli Lilly Obesity Drug Market

As a general trend from these comparisons, adherence to GLP-1 RAs seems to be better with lower injection frequencies

Part of what they look for is too-rapid weight loss which, in addition to straining vital body functions, can accelerate muscle loss

These trials are expected to run until 2026

Red blood cells live for roughly 120 days, making this measurement an excellent marker of glucose exposure over time

in 12 HFpEF patients who underwent bariatric surgery, an improvement in Minnesota Living With Heart Failure score (p=0.018), a lowering in LV myocardial mass (p=0.001) and a reduction in NYHA functional class of HF were observed at 3 and 6 months after surgery

Among 298 patients who were diagnosed with an ORC during the follow-up period, 77 (26 percent) were diagnosed with breast cancer, 49 (16 percent) were diagnosed with colon or rectum cancer, and 45 (15 percent) were diagnosed with uterine cancer